Growth factors in diabetic complications

Expert Review of Clinical Immunology

Volumn 2, Issue 3, 2006, Pages 403-418

  Thomson, Sally E ^a   McLennan, Susan V ^a   Twigg, Stephen M ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTOVEGIN; ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; BECAPLERMIN; CONNECTIVE TISSUE GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEMOGLOBIN A1C; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; RENIN; RENIN INHIBITOR; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BIOCHEMISTRY; CARDIOMYOPATHY; CLINICAL TRIAL; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOWN REGULATION; FIBROSIS; GENETIC SUSCEPTIBILITY; HEMODYNAMIC PARAMETERS; HUMAN; HYPERGLYCEMIA; IN VIVO STUDY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; REVIEW; TIME; TISSUE INJURY; TISSUE SPECIFICITY; ULCER HEALING; WOUND HEALING;

EID: 33748513485     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.2.3.403     Document Type: Review

References (150)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329(14), 977-986 (1993).
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131), 854-865 (1998).
3. Wong JML, Constantino M, Twigg SM, Yue DK. The metabolic syndrome in Type 2 diabetes is associated with gender, ethnicity and an increased prevalence of chronic end-organ complications. Diabetes Obes. Metab. (2006) (In Press).
4. Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M. Paraoxonase gene cluster is a genetic marker for early microvascular complications in Type 1 diabetes. Diabet. Med. 19(3), 212-215 (2002).
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865), 813-820 (2001).
6. van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol. Dial. Transplant. 20(1), 6-10 (2005).
7. Bennett SP, Griffiths GD, Schor AM, Leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br. J. Surg. 90(2), 133-146 (2003).
8. Martin P. Wound healing - aiming for perfect skin regeneration. Science 276(5309), 75-81 (1997).
9. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 26(3), 911-916 (2003).
10. Yokoyama H, Okudaira M, Otani T et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 58(1), 302-311 (2000).
11. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr. Rev. 25(6), 971-1010 (2004).
12. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43(10), 1205-1223 (2000).
13. Cooper ME, Gilbert RE, Epstein M. Pathophysiology of diabetic nephropathy. Metabolism 47(12 Suppl. 1), 3-6 (1998).
14. Castellino P, Tuttle KR, DeFronzo RA. Diabetic nephropathy. Curr. Ther. Endocrinol. Metab. 5, 426-436 (1994).
15. Mauer SM. Structural-functional correlations of diabetic nephropathy. Kidney Int. 45(2), 612-622 (1994).
16. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J. Clin. Invest. 74(4), 1143-1155 (1984).
17. Osterby R, Parving HH, Hommel E, Jorgensen HE, Lokkegaard H. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes 39(9), 1057-1063. (1990).
18. Riser BL, Cortes P, Yee J. Modelling the effects of vascular stress in mesangial cells. Curr. Opin. Nephrol. Hypertens. 9(1), 43-47 (2000).
19. Murphy M, Godson C, Cannon S et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J. Biol. Chem. 274(9), 5830-5834. (1999).
20. Adler S. Structure-function relationships in diabetic nephropathy: lessons and limitations. Kidney Int. Suppl. 60, S42-S45 (1997).
21. Ayo SH, Radnik RA, Glass WF II et al. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am. J. Physiol. 260(2 Pt 2), F185-F191 (1991).
22. McLennan SV, Fisher EJ, Yue DK, Turtle JR. High glucose concentration causes a decrease in mesangium degradation. A factor in the pathogenesis of diabetic nephropathy. Diabetes 43(8), 1041-1045 (1994).
23. Reckelhoff JF, Tygart VL, Mitias MM, Walcott JL. STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes 42(10), 1425-1432 (1993).
24. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc. Natl Acad. Sci. USA 89(24), 12043-12047 (1992).
25. Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol. Dial. Transplant. 11(Suppl. 5), 62-65 (1996).
26. Tack I, Elliot SJ, Potier M, Rivera A, Striker GE, Striker LJ. Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice. Diabetes 51(1), 182-188 (2002).
27. Oemar BS, Foellmer HG, Hodgdon-Anandant L, Rosenzweig SA. Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J. Biol. Chem. 266(4), 2369-2373 (1991).
28. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlet JA. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 48(2), 377-382 (1999).
29. Segev Y, Landau D, Marbach M, Shehadeh N, Flyvbjerg A, Phillip M. Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. J. Am. Soc. Nephrol. 8(3), 436-444 (1997).
30. Haylor J, Hickling H, El Eter E et al. JB3, an IGF-I receptor antagonist, inhibits early renal growth in diabetic and uninephrectomized rats. J. Am. Soc. Nephrol. 11(11), 2027-2035 (2000).
31. Verrotti A, Cieri F, Petitti MT, Morgese G, Chiarelli F. Growth hormone and IGF-I in diabetic children with and without microalbuminuria. Diabetes Nutr. Metab. 12(4), 271-276 (1999).
32. Kim NH, Jung HH, Cha DR, Choi DS. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J. Endocrinol. 165(3), 617-624 (2000).
33. Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem. 276(47), 43836-43841 (2001).
34. Pupilli C, Lasagni L, Romagnani P et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J. Am. Soc. Nephrol. 10(2), 245-255 (1999).
35. Saijonmaa O, Nyman T, Kosonen R, Fyhrquist F. Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor. Am. J. Physiol. Heart Circ. Physiol. 280(2), H885-H891 (2001).
36. Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int. 64(2), 468-479 (2003).
37. Cooper ME, Vranes D, Youssef S et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48(11), 2229-2239 (1999).
38. Hoshi S, Shu Y, Yoshida F et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab. Invest. 82(1), 25-35 (2002).
39. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental Diabetes J. Am. Soc. Nephrol. 12(5), 993-1000 (2001).
40. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J. Am. Soc. Nephrol. 7(5), 661-666 (1996).
41. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J. Clin. Invest. 90(1), 1-7. (1992).
42. Nakamura T, Miller D, Ruoslahti E, Border WA. Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β 1. Kidney Int. 41(5), 1213-1221 (1992).
43. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders, Philadelphia, PA, USA (2005).
44. Wolf G. Growth factors and the development of diabetic nephropathy. Curr. Diab. Rep. 3(6), 485-490 (2003).
45. Chen S, Cohen MP, Ziyadeh FN. Amadoriglycated albumin in diabetic nephropathy: pathophysiologic connections. Kidney Int. Suppl. 77, S40-S44. (2000).
46. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-β overexpression in proximal tubular cells. Kidney Int. 63(2), 464-473 (2003).
47. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-β. J. Clin. Invest. 93(2), 536-542 (1994).
48. Gilbert RE, Krum H, Wilkinson-Berka J, Kelly DJ. The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. Diabet. Med. 20(8), 607-621 (2003).
49. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am. J. Pathol. 158(5), 1653-1663 (2001).
50. Brosius FC III. Trophic factors and cytokines in early diabetic glomerulopathy. Exp. Diabesity Res. 4(4), 225-233 (2003).
51. Gilbert RE, Cox A, Wu LL et al. Expression of transforming growth factor-β1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition. Diabetes 47(3), 414-422 (1998).
52. Iwano M, Kubo A, Nishino T et al. Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int. 49(4), 1120-1126 (1996).
53. Sharma K, Ziyadeh FN, Alzahabi B et al. Increased renal production of transforming growth factor-β1 in patients with type II Diabetes Diabetes 46(5), 854-859 (1997).
54. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45(4), 522-530 (1996).
55. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGFβ-1 oligooxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am. J. Physiol. Renal Physiol. 278(4), F628-F634 (2000).
56. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-β2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J. Endocrinol. 170(3), 647-651 (2001).
57. Ito Y, Aten J, Bende RJ et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53(4), 853-861 (1998).
58. Twigg SM, Cooper ME. The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 47(6), 965-968 (2004).
59. Wahab NA, Weston BS, Roberts T, Mason RM. Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13(10), 2437-2445 (2002).
60. Riser BL, Denichilo M, Cortes P et al. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 11(1), 25-38 (2000).
61. McLennan SY, Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145(12), 5646-5655 (2004).
62. Twigg SM, Chen MM, Joly AH et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142(5), 1760-1769 (2001).
63. Twigg SM, Joly AH, Chen MM et al. Connective tissue growth factor/ IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143(4), 1260-1269 (2002).
64. Twigg SM, Cao Z, McLennan SV et al. Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology. 143(12), 4907-4915 (2002).
65. Ito Y, Goldschmeding R, Bende R et al. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J. Am. Soc. Nephrol. 12(3), 472-484 (2001).
66. Liu BC, Chen Q, Luo DD et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol. Sin. 24(1), 67-73 (2003).
67. Andersen S, van Nieuwenhoven FA, Tarnow L et al. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int. 67(6), 2325-2329 (2005).
68. Seppa H, Grotendorst G, Seppa S, Schiffmann E, Martin GR. Platelet-derived growth factor in chemotactic for fibroblasts. J. Cell Biol. 92(2), 584-588 (1982).
69. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79(4), 1283-1316 (1999).
70. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 48(1), 111-117 (1995).
71. Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 12(10), 2098-2107 (2001).
72. Langham RG, Kelly DJ, Maguire J, Dowling JP, Gilbert RE, Thomson NM. Over-expression of platelet-derived growth factor in human diabetic nephropathy. Nephrol. Dial. Transplant. 18(7), 1392-1396 (2003).
73. Gilbert RE, Cox A, McNally PG et al. Increased epidermal growth factor in experimental diabetes related kidney growth in rats. Diabetologia 40(7), 778-785 (1997).
74. Kelly DJ, Cox AJ, Tolcos M, Cooper ME, Wilkinson-Berka JL, Gilbert RE. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int. 61(1), 31-39 (2002).
75. Wassef L, Kelly DJ, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental Diabetes Kidney Int. 66(5), 1805-1814 (2004).
76. Wetzler C, Kampfer H, Stallmeyer B, Pfeilschifter J, Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 115(2), 245-253 (2000).
77. Pierce GF. Inflammation in nonhealing diabetic wounds: the space-time continuum does matter. Am. J. Pathol. 159(2), 399-403 (2001).
78. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen. 7(6), 423-432 (1999).
79. Philipp K, Riedel F, Sauerbier M, Hormann K, Germann G. Targeting TGF-β in human keratinocytes and its potential role in wound healing. Int. J. Mol. Med. 14(4), 589-593 (2004).
80. Shah M, Revis D, Herrick S et al. Role of elevated plasma transforming growth factor-β1 levels in wound healing. Am. J. Pathol. 154(4), 1115-1124 (1999).
81. Galiano RD, Tepper OM, Pelo CR et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am. J. Pathol. 164(6), 1935-1947 (2004).
82. Singer AJ, Clark RA. Cutaneous wound healing. N. Engl. J. Med. 341(10), 738-746 (1999).
83. Kubota S, Kawata K, Yanagita T, Doi H, Kitoh T, Takigawa M. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J. Biochem. (Tokyo) 136(3), 279-282 (2004).
84. da Costa Pinto FA, Malucelli BE. Inflammatory infiltrate, VEGF and FGF-2 contents during corneal angiogenesis in STZ-diabetic rats. Angiogenesis 5(1-2), 67-74 (2002).
85. Brown RL, Breeden MP, Greenhalgh DG. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J. Surg. Res. 56(6), 562-570 (1994).
86. Inkinen K, Wolff H, Lindroos P, Ahonen J. Connective tissue growth factor and its correlation to other growth factors in experimental granulation tissue. Connect Tissue Res. 44(1), 19-29 (2003).
87. Amery CM. Growth factors and the management of the diabetic foot. Diabet. Med. 22(Suppl. 1), 12-14 (2005).
88. Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl Acad. Sci. USA 83(12), 4167-4171 (1986).
89. Tredget EB, Demare J, Chandran G, Tredget EE, Yang L, Ghahary A. Transforming growth factor-β and its effect on reepithelialization of partial-thickness ear wounds in transgenic mice. Wound Repair Regen. 13(1), 61-67 (2005).
90. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell 4(6), 637-645 (1993).
91. O'Kane S, Ferguson MW. Transforming growth factor βs and wound healing. Int. J. Biochem. Cell Biol. 29(1), 63-78 (1997).
92. Cowin AJ, Hatzirodos N, Holding CA et al. Effect of healing on the expression of transforming growth factor β(s) and their receptors in chronic venous leg ulcers. J. Invest. Dermatol. 117(5), 1282-1289 (2001).
93. Crowe MJ, Doetschman T, Greenhalgh DG. Delayed wound healing in immunodeficient TGF-β 1 knockout mice. J. Invest. Dermatol. 115(1), 3-11 (2000).
94. Oemar BS, Luscher TF. Connective tissue growth factor. Friend or foe? Arterioscler. Thromb. Vasc. Biol. 17(8), 1483-1489. (1997).
95. Leask A, Abraham DJ. The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem. Cell Biol. 81(6), 355-363 (2003).
96. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol. 21(6), 473-482 (2002).
97. Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat. Cell Biol. 4(8), 599-604 (2002).
98. Inoki I, Shiomi T, Hashimoto G et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16(2), 219-221 (2002).
99. Mutsaers SE, Bishop JE, McGrouther G, Laurent GJ. Mechanisms of tissue repair: from wound healing to fibrosis. Int. J. Biochem. Cell Biol. 29(1), 5-17 (1997).
100. Medina A, Scott PG, Ghahary A, Tredget EE. Pathophysiology of chronic nonhealing wounds. J. Burn Care Rehabil. 26(4), 306-319 (2005).
101. Bauer EA, Cooper TW, Huang JS, Altman J, Deuel TF. Stimulation of in vitro human skin collagenase expression by platelet-derived growth factor. Proc. Natl Acad. Sci. USA 82(12), 4132-4136 (1985).
102. Fu X, Shen Z, Guo Z, Zhang M, Sheng Z. Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor. Chin. Med. J. (Engl.). 115(3), 331-335. (2002).
103. Robson MC, Dubay DA, Wang X, Franz MG. Effect of cytokine growth factors on the prevention of acute wound failure. Wound Repair Regen. 12(1), 38-43 (2004).
104. Mustoe TA, Pierce GF, Morishima C, Deuel TF. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J. Clin. Invest. 87(2), 694-703 (1991).
105. Nanney LB. Epidermal and dermal effects of epidermal growth factor during wound repair. J. Invest. Dermatol. 94(5), 624-629 (1990).
106. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nature Med. 9(6), 669-676 (2003).
107. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9(6), 653-660 (2003).
108. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48(10), 1899-1906 (1999).
109. Jain RK. Molecular regulation of vessel maturation. Nat. Med. 9(6), 685-693 (2003).
110. Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J. Invest. Dermatol. 106(4), 729-733 (1996).
111. Shimo T, Nakanishi T, Kimura Y et al. Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J. Biochem. (Tokyo) 124(1), 130-140 (1998).
112. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26(6), 1790-1795 (2003).
113. Bucalo BEWFV. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen. 1, 181-186 (1993).
114. Chesnoy S, Lee PY, Huang L. Intradermal injection of transforming growth factor-β1 gene enhances wound healing in genetically diabetic mice. Pharm. Res. 20(3), 345-350 (2003).
115. Loots MA, Lamme EN, Zeegelaar J, Mekkes JR, Bos JD, Middelkoop E. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J. Invest. Dermatol. 111(5), 850-857 (1998).
116. Ferguson MW, Herrick SE, Spencer MJ, Shaw JE, Boulton AJ, Sloan P. The histology of diabetic foot ulcers. Diabet. Med. 13(Suppl. 1), S30-S33 (1996).
117. Bitar MS, Labbad ZN. Transforming growth factor-β and insulin-like growth factor-I in relation to diabetes-induced impairment of wound healing. J. Surg. Res. 61(1), 113-119 (1996).
118. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 366(9498), 1736-1743 (2005).
119. Loots MA, Lamme EN, Mekkes JR, Bos JD, Middelkoop E. Cultured fibroblasts from chronic diabetic wounds on the lower extremity (non-insulin-dependent diabetes mellitus) show disturbed proliferation. Arch. Dermatol. Res. 291(2-3), 93-99 (1999).
120. Signorelli SS, Malaponte G, Libra M et al. Plasma levels and zymographic activities of matrix metalloproteinases 2 and 9 in type II diabetics with peripheral arterial disease. Vasc. Med. 10(1), 1-6 (2005).
121. Jeffcoate WJ, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab. Res. Rev. 20(Suppl. 1), S78-S89 (2004).
122. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 361(9368), 1545-1551 (2003).
123. Moulin V, Lawny F, Barritault D, Caruelle JP. Platelet releasate treatment improves skin healing in diabetic rats through endogenous growth factor secretion. Cell Mol. Biol. (Noisy-le-grand) 44(6), 961-971 (1998).
124. Lauer G, Sollberg S, Cole M et al. Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. J. Invest. Dermatol. 115(1), 12-18 (2000).
125. Michaels JT, Dobryansky M, Galiano RD et al. Topical vascular endothelial growth factor reverses delayed wound healing secondary to angiogenesis inhibitor administration. Wound Repair Regen. 13(5), 506-512 (2005).
126. Richard JL, Parer-Richard C, Daures JP et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, double-blind, placebo-controlled study. Diabetes Care 18(1), 64-69 (1995).
127. Jude EB, Blakytny R, Bulmer J, Boulton AJ, Ferguson MW. Transforming growth factor-β 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet. Med. 19(6), 440-447 (2002).
128. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A Phase III randomized placebo-controlled double-blind study. Diabetes Care 21(5), 822-827 (1998).
129. Eldor R, Raz I, Ben Yehuda A, Boulton AJ. New and experimental approaches to treatment of diabetic foot ulcers: a comprehensive review of emerging treatment strategies. Diabet. Med. 21(11), 1161-1173 (2004).
130. Tsang MW, Wong WK, Hung CS et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care 26(6), 1856-1861 (2003).
131. Brown RL, Breeden MP, Greenhalgh. PDGF and TGF-α act synergistically to improve wound healing in the genetically diabetic mouse. J. Surg. Research 56, 562-570 (1994).
132. Eming SA, Krieg T, Davidson JM. Gene transfer in tissue repair: status, challenges and future directions. Expert Opin. Biol. Ther. 4(9), 1373-1386 (2004).
133. Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes. Metab. 3(5), 332-337 (2001).
134. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 350(9081), 855-859 (1997).
135. Lazareth I. [Local care and medical treatment for ischemic diabetic ulcers]. J. Mal. Vasc. 27(3), 157-163 (2002).
136. de Lalla F, Pellizzer G, Strazzabosco M et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob. Agents Chemother. 45(4), 1094-1098 (2001).
137. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl Acad. Sci. USA 92(23), 10457-10461 (1995).
138. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr. Pharm. Des. 10(27), 3331-3348 (2004).
139. Letterio JJ, Bottinger EP. TGF-β knockout and dominant-negative receptor transgenic mice. Miner Electrolyte Metab. 24(2-3), 161-167 (1998).
140. Goss JR, Natsume A, Wolfe D, Mata M, Glorioso JC, Fink DJ. Delivery of herpes simplex virus-based vectors to the nervous system. Methods Mol. Biol. 246, 309-322 (2004).
141. Zhang W, Feng J, Li Y, Guo N, Shen B. Humanization of an anti-human TNF-α antibody by variable region resurfacing with the aid of molecular modeling. Mol. Immunol. 42(12), 1445-1451 (2005).
142. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov. 4(12), 1015-1026 (2005).
143. Steed DL, Goslen JB, Holloway GA, Malone JM, Bunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. Diabetes Care 15(11), 1598-1604 (1992).
144. Schratzberger P, Walter DH, Rittig K et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107(9), 1083-1092 (2001).
145. Yoon YS, Uchida S, Masuo O et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111(16), 2073-2085 (2005).
146. Ahmad FK, He Z, King GL. Molecular targets of diabetic cardiovascular complications. Curr. Drug Targets 6(4), 487-494 (2005).
147. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 339(2), 69-75 (1998).
148. Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 27(3), 752-757 (2004).
149. Lum C, Shesely EG, Potter DL, Beierwaltes WH. Cardiovascular and renal phenotype in mice with one or two renin genes. Hypertension 43(1), 79-86 (2004).
150. Marston WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 26(6), 1701-1705 (2003).